GSK launches phase 3 programme for gepotidacin in uUTI and GC
The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2.
As per the terms of the deal, Sartorius Stedim will be acquiring Danaher’s label-free biomolecular characterization, chromatography hardware and resins, and the SoloHill business. The chromatography business is